Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Oncology
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Shanghai Henlius Biotechnology
Pharma
China IIT, Daiichi Sankyo-AZ, Leo-Tanabe—Fierce Pharma Asia
China's alternative trial pathway draws scrutiny. AZ and Daiichi Sankyo's phase 3 lung cancer win. Tanabe's licensing deal. And more.
Donavyn Coffey
Aug 21, 2026 9:00am
Sandoz, Henlius agree to $322M deal for 3 biosimilars
Aug 17, 2026 10:46am
Lilly-Innovent, AstraZeneca, Madrigal—Fierce Pharma Asia
Feb 13, 2026 8:25am
Supply chain ties, Bayer biotech incubator—Fierce Pharma Asia
Nov 21, 2025 8:00am
Poherdy, first biosimilar to Roche's Perjeta, scores FDA nod
Nov 14, 2025 10:52am
BMS JV sale, biotech debuts, possible deals—Fierce Pharma Asia
Sep 19, 2025 8:36am
